kevin j pridham
Thermo Fisher Scientific (United States)
San Jose, United States
Review Editor
Cancer Molecular Targets and Therapeutics
- Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Editorial Board
Type at least 3 characters
669 editors
Shape the future of research in your field
Join the board
Editors
Review Editors
marianna prokopi
Cyprus University of Technology
Limassol, Cyprus
Review Editor
Cancer Molecular Targets and Therapeutics
lei qi
University of Kentucky
Lexington, United States
Review Editor
Cancer Molecular Targets and Therapeutics
liren qian
Department of Hematology, Fifth Medical Center of the PLA General Hospital
Beijing, China
Review Editor
Cancer Molecular Targets and Therapeutics
kang qin
University of Texas MD Anderson Cancer Center
Houston, United States
Review Editor
Cancer Molecular Targets and Therapeutics
georgios (george) rassidakis
National and Kapodistrian University of Athens
Athens, Greece
Review Editor
Cancer Molecular Targets and Therapeutics
tricarico rossella
Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia
Pavia, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
daniel c rabe
Tempus Labs (United States)
Chicago, United States
Review Editor
Cancer Molecular Targets and Therapeutics
mohamed rahmani
Khalifa University
Abu Dhabi, United Arab Emirates
Review Editor
Cancer Molecular Targets and Therapeutics
rajani rai
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Review Editor
Cancer Molecular Targets and Therapeutics
kanak raina
Halda Therapeutics
New Haven, United States
Review Editor
Cancer Molecular Targets and Therapeutics
karishma rajani
Mayo Clinic
Rochester, United States
Review Editor
Cancer Molecular Targets and Therapeutics
gian luca rampioni vinciguerra
Sapienza University of Rome
Rome, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
xiongjian rao
University of Kentucky
Lexington, United States
Review Editor
Cancer Molecular Targets and Therapeutics
reyaz ur rasool
University of Pennsylvania
Philadelphia, United States
Review Editor
Cancer Molecular Targets and Therapeutics
gulam m rather
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey
New Brunswick, United States
Review Editor
Cancer Molecular Targets and Therapeutics